Private company

Coeptis Therapeutics Inc.

Coeptis Therapeutics Inc. is an American pharmaceutical preparations company based in Wexford.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersWexford, Pennsylvania1
  • Incorporated inDE2
  • Business address105 Bradford Rd, Suite 420, Wexford, Pa 150902
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

100.0%Gross margin3
-18977.4%Operating margin3
-17932.4%Net margin3
143.8%Revenue growth, 20213
-572.2%Return on equity3
0.70×Debt to equity3
-$4.5MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Interest100¢$187.1K

Out of $75.0K in revenue.3 The company lost money this year.

Financial statements

Revenue3$75.0K in 2021+144% since 2020
0$20.0K$40.0K$60.0K$80.0K2020: $30.8K$30.8K20202021: $75.0K$75.0K2021+144%
Gross profit3$75.0K in 2021
-$1.0M-$500.0K0$500.0K2020: -$933.5K-$933.5K20202021: $75.0K$75.0K2021
Operating income3-$14.2M in 2021+107% since 2020
-$15.0M-$10.0M-$5.0M02020: -$6.9M-$6.9M20202021: -$14.2M-$14.2M2021+107%
Net income3-$13.4M in 2021+47% since 2020
-$15.0M-$10.0M-$5.0M02020: -$9.2M-$9.2M20202021: -$13.4M-$13.4M2021+47%
Fiscal year201920202021
Revenue$30.8K3$75.0K3
Cost of revenue$964.2K3$03
Gross profit-$933.5K3$75.0K3
Research and development$3.5K3$03
Operating expenses$14.3M3
Operating income-$6.9M3-$14.2M3
Interest$148.2K3$187.1K3
Income before tax-$13.4M3
Income tax$03$03
Net income-$9.2M3-$13.4M3

Compare Coeptis Therapeutics Inc. with another company

Corporate structure

Coeptis Therapeutics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Coeptis Therapeutics Inc.

  • Thomas Hutchinson Filed SC 13G on Coeptis Therapeutics Inc., latest Sep 19, 2022
  • Coeptis Therapeutics Inc. Wexford, Pennsylvania

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Coeptis Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$25.2K3 Dec 31, 2021$25.2K3 Dec 31, 20200%
Accumulated depreciation$11.3K3 Dec 31, 2021$9.7K3 Dec 31, 2020+16.2%
Property and equipment, net$13.9K3 Dec 31, 2021$15.5K3 Dec 31, 2020−10.2%
Operating-lease assets (leased space)$17.9K3 Dec 31, 2021$58.2K3 Dec 31, 2020−69.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.4K6 Dec 31, 2020$9.1K6 Feb 29, 2020−30.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$03 Dec 31, 2021$03 Dec 31, 2020

Leadership

Who has led Coeptis Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Mehalick2021

President

  1. David Mehalick2021

Chief financial officer

  1. Christine Elise Sheehy2021
2025
Board members and other officers (4)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorMichael Handley named Oct 12, 202110

Former names

  • VININGS HOLDINGS, INC.Aug 12, 2020 to May 18, 20212

Timeline

  1. Oct 28, 20228-K Shareholder vote11
  2. Sep 21, 20228-K Regulation FD disclosure; Other events12
  3. Sep 7, 20228-K Entered a material agreement; Regulation FD disclosure13
  4. Aug 22, 20228-K Ended a material agreement14
  5. Jul 6, 20228-K Regulation FD disclosure; Other events15
  6. May 17, 20228-K Other events16
  7. Apr 19, 20228-K Entered a material agreement; Regulation FD disclosure17
  8. Apr 12, 20228-K Entered a material agreement18
  9. Apr 5, 20228-K Executive or director change19
  10. Feb 25, 20228-K Entered a material agreement; Executive or director change20
  11. Dec 27, 20218-K Entered a material agreement21
  12. Oct 1, 20218-K Ended a material agreement22
  13. Feb 19, 2021New chief executive David Mehalick becomes CEO7

Filings

46 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 12 major events, 1 insider forms, 1 large holders, 1 private raises, 26 other. The latest 20:

  1. Dec 14, 202215-12G TERMINATION OF REGISTRATION EDGAR
  2. Nov 8, 202210-Q EDGAR
  3. Oct 28, 20228-K CURRENT REPORT EDGAR
  4. Sep 30, 2022DEFM14A DEFINITIVE PROXY STATEMENT EDGAR
  5. Sep 21, 2022DEFA14A FORM 8-K EDGAR
  6. Sep 21, 20228-K EDGAR
  7. Sep 19, 2022SC 13G SCHEDULE 13G EDGAR
  8. Sep 16, 2022PREM14A PRELIMINARY PROXY STATEMENT EDGAR
  9. Sep 7, 2022253G2 OFFERING CIRCULAR SUPPLEMENT EDGAR
  10. Sep 7, 2022DEFA14A FORM 8-K EDGAR
  11. Sep 7, 20228-K EDGAR
  12. Aug 22, 2022DEFA14A FORM 8-K EDGAR
  13. Aug 22, 20228-K EDGAR
  14. Aug 15, 2022UPLOAD EDGAR
  15. Aug 8, 2022CORRESP EDGAR
  16. Aug 4, 2022UPLOAD EDGAR
  17. Aug 3, 2022CORRESP EDGAR
  18. Aug 2, 202210-Q EDGAR
  19. Jul 20, 2022UPLOAD EDGAR
  20. Jul 7, 2022CORRESP EDGAR

The 46 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 16, 2021Mehalick DavidCEO and PresidentSale1,200,000Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Thomas HutchinsonSC 13G, 1 filing Sep 19, 202223

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 12, 2021Raised $5.5 million in a private offering of equity Form D: $9 million offered in all Form D

SEC filer profile

How Coeptis Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCoeptis Therapeutics Inc.1
  • CIK0001819663
  • Employer ID (EIN)84-39981171
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address105 Bradford Rd, Suite 420, Wexford, PA 150901
  • Phone724-934-64671
  • Shares outstanding19,516,373 as of Nov 7, 20225
  • Public float$32.1M as of Jun 30, 20213
  • On EDGAR sinceAug 12, 20201
  • Filings73 in all: 8-K (21), 10-Q (8), UPLOAD (6), CORRESP (5), DEFA14A (5), 3 (3), SC 13G (3), 10-Q/A (2)1
    All 26 form types

    D (2), D/A (2), 1-A (1), 10-12G (1), 10-K (1), 10-KT (1), 15-12G (1), 253G1 (1), 253G2 (1), 4 (1), 8-K/A (1), DEFM14A (1), NT 10-Q (1), PREM14A (1), QUALIF (1), RW (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2022
    Quarterly report (10-Q) Nov 8, 2022
    Latest 8-K (8-K) Oct 28, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23